Two retrospective studies from Italy showed that patients with Luminal B breast cancer had a shorter time to progression when treated either with endocrine therapy and a CDK4/6 inhibitor [22] or with first-line endocrine therapy alone [23]. Here, CDK4 is linked to breast cancer.